Mien Chie Hung


Affiliation: The University of Texas
Country: USA


  1. Dong Q, Du Y, Li H, Liu C, Wei Y, Chen M, et al. EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Res. 2019;79:819-829 pubmed publisher
    ..SIGNIFICANCE: Regulation of PARP by the c-MET and EGFR heterodimer suggests a potentially effective combination therapy to sensitize HCC to PARPi. ..
  2. Lin C, Chen H, Huang C, Lai L, Lu T, Tseng G, et al. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Res. 2014;74:5229-43 pubmed publisher
    ..Our results show how ADAM9 regulates lung cancer metastasis to the brain by facilitating the tPA-mediated cleavage of CDCP1, with potential implications to target this network as a strategy to prevent or treat brain metastatic disease. ..
  3. Li H, Li C, Li X, Ding Q, Guo L, Liu S, et al. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. 2019;156:1849-1861.e13 pubmed publisher
    ..Combined with a MET inhibitor, anti-PD1 and anti-PDL1 produced additive effect to slow growth of HCCs in mice. ..
  4. Lee P, Fang Y, Yamaguchi H, Wang W, Chen T, Hong X, et al. Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. Cancer Cell. 2018;34:954-969.e4 pubmed publisher
    ..Moreover, the level of nuclear PKCδ is associated with TKI response in patients. The combined inhibition of PKCδ and EGFR induces marked regression of resistant NSCLC tumors with EGFR mutations. ..
  5. Wang Y, Lee H, Hung M. A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases. J Biomed Sci. 2018;25:83 pubmed publisher
  6. Hsu J, Li C, Lai Y, Hung M. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. Cancer Res. 2018;78:6349-6353 pubmed publisher
    ..i>Cancer Res; 78(22); 6349-53. ©2018 AACR. ..
  7. Cha J, Yang W, Xia W, Wei Y, Chan L, Lim S, et al. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018;71:606-620.e7 pubmed publisher
    ..Our findings identify a new regulatory mechanism of PD-L1 expression through the ERAD pathway and suggest that the metformin-CTLA4 blockade combination has the potential to increase the efficacy of immunotherapy. ..
  8. Li C, Lai Y, Hsu J, Hung M. Activation of phagocytosis by immune checkpoint blockade. Front Med. 2018;12:473-480 pubmed publisher
    ..Therefore, identification of biomarkers and combinatorial therapeutic strategies, have the potential to improve the efficacy and safety profiles of current immunotherapies. ..
  9. Shen J, Hung M. Signaling-mediated regulation of MicroRNA processing. Cancer Res. 2015;75:783-91 pubmed publisher
    ..Here, we review the current findings in signaling-mediated miRNA processing as well as their potential clinical relevance in cancer. ..

More Information


  1. Thirumurthi U, Shen J, Xia W, Labaff A, Wei Y, Li C, et al. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Sci Signal. 2014;7:ra71 pubmed publisher
    ..Thus, stabilizing SIRT6 may be a clinical strategy for overcoming trastuzumab resistance in breast cancer patients. ..
  2. Chou C, Huang P, Tsou P, Wei Y, Lee H, Wang Y, et al. A flow-proteometric platform for analyzing protein concentration (FAP): Proof of concept for quantification of PD-L1 protein in cells and tissues. Biosens Bioelectron. 2018;117:97-103 pubmed publisher
    ..Therefore, FAP is a simple, faster, and reliable method to measure the protein concentration in cells and tissues, which can support the conventional methods such as WB and IHC to determine the actual protein level. ..
  3. Yang W, Cha J, Xia W, Lee H, Chan L, Wang Y, et al. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression. Cancer Res. 2018;78:3761-3768 pubmed publisher
    ..i>Cancer Res; 78(14); 3761-8. ©2018 AACR. ..
  4. Wang Y, Lee H, Chou C, Yang W, Wei Y, Chen C, et al. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell. 2018;33:752-769.e8 pubmed publisher
    ..These results identify a role of ANG as a serum biomarker that may be used to stratify patients for EGFR-targeted therapies, and offer insights into the ligand-receptor relationship between RNase and RTK families. ..
  5. Hsu J, Xia W, Hsu Y, Chan L, Yu W, Cha J, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9:1908 pubmed publisher
    ..Together, our results link MET to PD-L1 stabilization through glycosylation regulation and reveal it as a potential strategy to enhance cancer immunotherapy efficacy. ..
  6. Wu T, Chang S, Li C, Hsu Y, Chen T, Lee W, et al. Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-?B Pathway-Mediated Epithelial-Mesenchymal Transition after Resection. Clin Cancer Res. 2016;22:1800-12 pubmed publisher
    ..These findings suggest that controlling liver inflammation and/or targeting NF-?B-mediated Snail expression may be a potential therapeutic strategy to prevent hepatocellular carcinoma recurrence after hepatectomy. ..
  7. Li C, Xia W, Lim S, Hsu J, Huo L, Wu Y, et al. AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res. 2016;76:1451-62 pubmed publisher
  8. Hung M, Yang R, Sun Y. Powering Tumor Metastasis with Recycled Fuel. Cancer Cell. 2016;30:374-375 pubmed publisher
    ..In this issue, Ye et al. identify GOLM1 as a cargo adaptor that drives hepatocellular carcinoma metastasis by promoting EGFR recycling and provide insights into how this process is regulated. ..
  9. Li C, Lim S, Chung E, Kim Y, Park A, Yao J, et al. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018;33:187-201.e10 pubmed publisher
    ..Our work suggests targeting protein glycosylation as a potential strategy to enhance immune checkpoint therapy. ..
  10. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M, Hsu J, et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017;23:3711-3720 pubmed publisher
    ..i>Clin Cancer Res; 23(14); 3711-20. ©2017 AACR. ..
  11. Lim S, Li C, Xia W, Lee H, Chang S, Shen J, et al. EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Res. 2016;76:1284-96 pubmed publisher
    ..Our results illustrate how jointly targeting the EGFR/F1,6BP signaling axis may offer an immediately applicable therapeutic strategy to treat TNBC. ..
  12. Wan L, Xu K, Wei Y, Zhang J, Han T, Fry C, et al. Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Mol Cell. 2018;69:279-291.e5 pubmed publisher
    ..Our finding suggests that AMPK agonists might be promising sensitizers for EZH2-targeting cancer therapies. ..
  13. Li C, Lim S, Hsu J, Hung M. Rational combination of immunotherapy for triple negative breast cancer treatment. Chin Clin Oncol. 2017;6:54 pubmed publisher
  14. Yang R, Hung M. The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy. Sci China Life Sci. 2017;60:1058-1064 pubmed publisher
    ..In this article, we briefly describe the current knowledge of common checkpoint resistance mechanisms, focusing on the Tim-3/Gal-9 pathway as an alternative checkpoint that holds great promise as another target for ICB. ..
  15. Hsu J, Hung M. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016;35:575-588 pubmed publisher
    ..In this review, we provide a brief summary on the role of a selected number of RTKs in breast cancer and describe some mechanisms of resistance to targeted therapies. ..
  16. Lim S, Li C, Xia W, Cha J, Chan L, Wu Y, et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30:925-939 pubmed publisher
    ..CSN5 inhibits the ubiquitination and degradation of PD-L1. Inhibition of CSN5 by curcumin diminished cancer cell PD-L1 expression and sensitized cancer cells to anti-CTLA4 therapy. ..
  17. Wang Y, Hsu J, Kang Y, Wei Y, Lee P, Chang S, et al. Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. Cancer Res. 2016;76:7049-7058 pubmed
    ..Taken together, our results identified a new posttranslational modification of Gli1 that underlies its pivotal oncogenic functions in PDAC. Cancer Res; 76(23); 7049-58. ©2016 AACR. ..
  18. Chiou G, Chien C, Wang M, Chen M, Yang Y, Yu Y, et al. Epigenetic regulation of the miR142-3p/interleukin-6 circuit in glioblastoma. Mol Cell. 2013;52:693-706 pubmed publisher
    ..Collectively, we discovered an IL-6/miR142-3p feedback-loop-dependent regulation of GBM malignancy that could be a potential therapeutic target. ..